Study design
This is a single institutional one-arm prospective phase II clinical trial, including patients with GC and PC. This study was initiated in July 2022 and is expected to last for 3 years.The study was approved by the Hospital Ethics Committee (NP 1507/19) and the National Ethics Committee and registered at Plataforma Brasil (CAAE: 26306419.8.0000.0065; https://plataformabrasil.saude.gov.br). The study protocol was registered at ClinicalTrials.gov (NCT05541146).